The state of Florida currently has 29 active clinical trials seeking participants for Type 2 Diabetes research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472
Recruiting
The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO. Participation in the study will last about 18 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Accel Research Sites - DeLand Clinical Research Unit, DeLand, Florida +4 locations
Conditions: Obesity, Overweight, Type 2 Diabetes
Register for Updates
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
NCT06112418
Recruiting
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
07/15/2025
Locations: Flourish Medical Research, Boca Raton, Florida +13 locations
Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
Register for Updates
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
NCT06797869
Recruiting
This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: My Preferred Research, Miami, Florida +2 locations
Conditions: Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
Register for Updates
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
NCT06926842
Recruiting
The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: Innovative Research of West Florida, Clearwater, Florida +3 locations
Conditions: Overweight, Type 2 Diabetes, Obesity
Register for Updates
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475
Recruiting
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/01/2025
Locations: Renstar Medical Research, Ocala, Florida +1 locations
Conditions: Type 2 Diabetes
Register for Updates
Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus
NCT07055516
Recruiting
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NT-0796 as an Adjunct to a Reduced Calorie Diet and Increased Physical Activity in Obese Participants With/Without Type 2 Diabetes over a 6 months treatment period.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/27/2025
Locations: Investigative site, Cooper City, Florida +2 locations
Conditions: Obesity and Type 2 Diabetes
Register for Updates
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792
Recruiting
The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Accel Research Sites - DeLand Clinical Research Unit, DeLand, Florida +4 locations
Conditions: Obesity, Overweight, Type 2 Diabetes
Register for Updates
Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis
NCT06993454
Recruiting
The overall aim of this study is to investigate the effects of exercise on the amount of glucose that is made by the liver in people with and without Type 2 diabetes (T2D) and hepatic steatosis (fatty liver).
Gender:
ALL
Ages:
Between 25 years and 55 years
Trial Updated:
05/20/2025
Locations: AdventHealth Translational Research Institute, Orlando, Florida
Conditions: Type 2 Diabetes, Hepatic Steatosis
Register for Updates
DISCOVERY of Risk Factors for Type 2 Diabetes in Youth
NCT06525259
Recruiting
The goal of the DISCOVERY study is to provide innovative critical information regarding the unique natural history of glycemic control, insulin sensitivity, and β-cell function, and their mechanistic determinates, in obese adolescents at risk for developing type 2 diabetes.
Gender:
ALL
Ages:
Between 9 years and 14 years
Trial Updated:
05/07/2025
Locations: Johns Hopkins All Children's Hospital, St. Petersburg, Florida
Conditions: Diabetes Mellitus Type 2, Childhood-Onset
Register for Updates
A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM
NCT06897202
Recruiting
This study is designed to test how well once-weekly MET097 (an ultra-long-acting GLP-1 receptor agonist) works to treat adults with obesity or overweight and type 2 diabetes mellitus (T2DM) compared to placebo. MET097 or placebo will be administered to individuals via subcutaneous injection once weekly for 28 weeks. If an individual is randomly assigned to MET097 they will receive one of four different dose regimens.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/09/2025
Locations: Research Site 097202-001001, Hollywood, Florida +1 locations
Conditions: Obesity in Diabetes, Type 2 Diabetes Mellitus (T2DM)
Register for Updates
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
NCT04501406
Recruiting
To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
04/02/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Steatohepatitis
Register for Updates
The Role of Type 2 Diabetes on Skeletal Muscle Atrophy and Recovery Following Bed Rest in Older Adults
NCT03761446
Recruiting
The goal of this study is to determine the impact of pre-diabetes and type 2 diabetes on muscle atrophy during a period of bed rest and recovery of muscle mass, strength, and physical function following bed rest.
Gender:
ALL
Ages:
Between 60 years and 80 years
Trial Updated:
03/12/2025
Locations: Translational Research Institute for Metabolism and Diabetes, Orlando, Florida
Conditions: Muscle Atrophy, Aging, Sedentary Behavior, Type 2 Diabetes, Pre-diabetes
Register for Updates